Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Review

Identification and manipulation of tumor associated macrophages in human cancers

Authors: Moniek Heusinkveld, Sjoerd H van der Burg

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Evading immune destruction and tumor promoting inflammation are important hallmarks in the development of cancer. Macrophages are present in most human tumors and are often associated with bad prognosis. Tumor associated macrophages come in many functional flavors ranging from what is known as classically activated macrophages (M1) associated with acute inflammation and T-cell immunity to immune suppressive macrophages (M2) associated with the promotion of tumor growth. The role of these functionally different myeloid cells is extensively studied in mice tumor models but dissimilarities in markers and receptors make the direct translation to human cancer difficult. This review focuses on recent reports discriminating the type of infiltrating macrophages in human tumors and the environmental cues present that steer their differentiation. Finally, immunotherapeutic approaches to interfere in this process are discussed.
Appendix
Available only for authorised users
Literature
1.
Steinman RM, Idoyaga J: Features of the dendritic cell lineage. Immunol Rev. 2010, 234: 5-17.PubMed
2.
Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity. 2010, 32: 593-604.PubMed
3.
Mantovani A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol. 2010, 22: 231-237.PubMed
4.
Kreider T, Anthony RM, Urban JF, Gause WC: Alternatively activated macrophages in helminth infections. Curr Opin Immunol. 2007, 19: 448-453.PubMedCentralPubMed
5.
Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010, 11: 889-896.PubMed
6.
Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23: 549-555.PubMed
7.
8.
Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J: Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol. 2005, 175: 342-349.PubMed
9.
Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141: 39-51.PubMed
10.
Porta C, Riboldi E, Sica A: Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 2011, 305: 250-262.PubMed
11.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674.PubMed
12.
Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC: Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 2011,
13.
Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P: Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis. 2007, 24: 121-130.PubMed
14.
Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP: Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 2011, 52: 643-650.PubMed
15.
Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, Sugarbaker DJ: Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer. 2011, 117: 1534-1544.
16.
Caillou B, Talbot M, Weyemi U, Pioche-Durieu C, Al GA, Bidart JM: Tumor-associated macrophages (TAMs) form an interconnected cellular supportive network in anaplastic thyroid carcinoma. PLoS One. 2011, 6: e22567-PubMedCentralPubMed
17.
Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI: Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011, 128: 703-711.PubMedCentralPubMed
18.
Chen J, Yao Y, Gong C, Yu F, Su S, Chen J: CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011, 19: 541-555.PubMedCentralPubMed
19.
Espinosa I, Jose CM, Catasus L, Canet B, D'angelo E, Zannoni GF: Myometrial invasion and lymph node metastasis in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol. 2010, 34: 1708-1714.PubMed
20.
Figel AM, Brech D, Prinz PU, Lettenmeyer UK, Eckl J, Turqueti-Neves A: Human renal cell carcinoma induces a dendritic cell subset that uses T-cell crosstalk for tumor-permissive milieu alterations. Am J Pathol. 2011, 179: 436-451.PubMedCentralPubMed
21.
Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007, 13: 1472-1479.PubMed
22.
Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL, Deavers M: Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res. 2007, 13: 5736-5744.PubMed
23.
Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT: Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression--clinicopathological correlation. Gynecol Oncol. 2007, 105: 157-165.PubMed
24.
Hasita H, Komohara Y, Okabe H, Masuda T, Ohnishi K, Lei XF: Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010, 101: 1913-1919.PubMed
25.
Jensen TO, Schmidt H, Moller HJ, Hoyer M, Maniecki MB, Sjoegren P: Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol. 2009, 27: 3330-3337.PubMed
26.
Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS: Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol. 2010, 102: 242-248.PubMed
27.
Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M: Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int. 2009, 59: 300-305.PubMed
28.
Komohara Y, Ohnishi K, Kuratsu J, Takeya M: Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008, 216: 15-24.PubMed
29.
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006, 203: 871-881.PubMedCentralPubMed
30.
Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P: Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007, 67: 8900-8905.PubMed
31.
Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F: Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res. 2011, 167: e211-e219.PubMed
32.
Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S: Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res. 2008, 14: 1423-1430.PubMed
33.
Ma J, Liu L, Che G, Yu N, Dai F, You Z: The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010, 10: 112-PubMedCentralPubMed
34.
Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C: Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T-cell response against tumor-associated antigens and survival. J Transl Med. 2007, 5: 62-PubMedCentralPubMed
35.
Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, Hashikawa K: Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int. 2010, 60: 278-283.PubMed
36.
Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M: Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011, 107: 1918-1922.PubMed
37.
Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J. 2009, 33: 118-126.PubMed
38.
Ohri CM, Shikotra A, Green RH, Waller DA, Bradding P: Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer. BMC Cancer. 2010, 10: 172-PubMedCentralPubMed
39.
Osinsky S, Bubnovskaya L, Ganusevich I, Kovelskaya A, Gumenyuk L, Olijnichenko G: Hypoxia, tumour-associated macrophages, microvessel density, VEGF and matrix metalloproteinases in human gastric cancer: interaction and impact on survival. Clin Transl Oncol. 2011, 13: 133-138.PubMed
40.
Rigo A, Gottardi M, Zamo A, Mauri P, Bonifacio M, Krampera M: Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer. 2010, 9: 273-PubMedCentralPubMed
41.
Ryder M, Ghossein RA, Ricarte-Filho JC, Knauf JA, Fagin JA: Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer. 2008, 15: 1069-1074.PubMedCentralPubMed
42.
Sanchez-Martin L, Estecha A, Samaniego R, Sanchez-Ramon S, Vega MA, Sanchez-Mateos P: The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood. 2011, 117: 88-97.PubMed
43.
Shabo I, Stal O, Olsson H, Dore S, Svanvik J: Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. Int J Cancer. 2008, 123: 780-786.PubMed
44.
Shieh YS, Hung YJ, Hsieh CB, Chen JS, Chou KC, Liu SY: Tumor-associated macrophage correlated with angiogenesis and progression of mucoepidermoid carcinoma of salivary glands. Ann Surg Oncol. 2009, 16: 751-760.PubMed
45.
Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 2010, 362: 875-885.PubMedCentralPubMed
46.
Takayama H, Nonomura N, Nishimura K, Oka D, Shiba M, Nakai Y: Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer. BJU Int. 2009, 103: 470-474.PubMed
47.
Tzankov A, Matter MS, Dirnhofer S: Refined prognostic role of CD68-positive tumor macrophages in the context of the cellular micromilieu of classical Hodgkin lymphoma. Pathobiology. 2010, 77: 301-308.PubMed
48.
van Dongen M, Savage ND, Jordanova ES, Briaire-de Bruijn IH, Walburg KV, Ottenhoff TH: Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors. Int J Cancer. 2010, 127: 899-909.PubMed
49.
Webster JA, Beck AH, Sharma M, Espinosa I, Weigelt B, Schreuder M: Variations in stromal signatures in breast and colorectal cancer metastases. J Pathol. 2010, 222: 158-165.PubMedCentralPubMed
50.
Yang X, Dong Y, Zhao J, Sun H, Deng Y, Fan J: Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Pract. 2007, 203: 499-505.PubMed
51.
Zeni E, Mazzetti L, Miotto D, Lo CN, Maestrelli P, Querzoli P: Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J. 2007, 30: 627-632.PubMed
52.
Algars A, Irjala H, Vaittinen S, Huhtinen H, Sundstrom J, Salmi M: Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int J Cancer. 2011
53.
Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002, 196: 254-265.PubMed
54.
Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A: Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer. 2007, 109: 556-565.PubMed
55.
Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L: Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood. 2007, 110: 587-595.PubMed
56.
Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J: Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 2010, 70: 5728-5739.PubMed
57.
Pettersen JS, Fuentes-Duculan J, Suarez-Farinas M, Pierson KC, Pitts-Kiefer A, Fan L: Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol. 2011, 131: 1322-1330.PubMedCentralPubMed
58.
Gadiot J, Hooijkaas AI, Kaiser AD, van TH, van BH, Blank C: Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011, 117: 2192-2201.PubMed
59.
Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM: Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res. 2009, 15: 6341-6347.PubMed
60.
McLean MH, Murray GI, Stewart KN, Norrie G, Mayer C, Hold GL: The inflammatory microenvironment in colorectal neoplasia. PLoS One. 2011, 6: e15366-PubMedCentralPubMed
61.
Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW: High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67: 354-361.PubMed
62.
Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004, 10: 942-949.PubMed
63.
Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG: Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?. Clin Cancer Res. 2008, 14: 2028-2035.PubMed
64.
Takahashi A, Kono K, Ichihara F, Sugai H, Amemiya H, Iizuka H: Macrophages in tumor-draining lymph node with different characteristics induce T-cell apoptosis in patients with advanced stage-gastric cancer. Int J Cancer. 2003, 104: 393-399.PubMed
65.
Pander J, Heusinkveld M, van der Straaten T, Jordanova ES, Baak-Pablo R, Gelderblom H: Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. Clin Cancer Res. 2011, 17: 5668-5673.PubMed
66.
Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ: M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011, 187: 1157-1165.PubMed
67.
Verreck FA, de BT, Langenberg DM, van der Zanden L, Ottenhoff TH: Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. J Leukoc Biol. 2006, 79: 285-293.PubMed
68.
Maniecki MB, Etzerodt A, Moestrup SK, Moller HJ, Graversen JH: Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression. Immunobiology. 2011, 216: 882-890.PubMed
69.
Mantovani A, Sica A, Allavena P, Garlanda C, Locati M: Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol. 2009, 70: 325-330.PubMed
70.
Martin MD, Matrisian LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007, 26: 717-724.PubMed
71.
Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006, 177: 7303-7311.PubMed
72.
Murray PJ, Wynn TA: Obstacles and opportunities for understanding macrophage polarization. J Leukoc Biol. 2011, 89: 557-563.PubMedCentralPubMed
73.
Pilling D, Fan T, Huang D, Kaul B, Gomer RH: Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS One. 2009, 4: e7475-PubMedCentralPubMed
74.
Puig-Kroger A, Sierra-Filardi E, Dominguez-Soto A, Samaniego R, Corcuera MT, Gomez-Aguado F: Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res. 2009, 69: 9395-9403.PubMed
75.
Van Gorp H, Delputte PL, Nauwynck HJ: Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 2010, 47: 1650-1660.PubMed
76.
Xu W, Schlagwein N, Roos A, van den Berg TK, Daha MR, van KC: Human peritoneal macrophages show functional characteristics of M-CSF-driven anti-inflammatory type 2 macrophages. Eur J Immunol. 2007, 37: 1594-1599.PubMed
77.
Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809.PubMed
78.
Avila-Moreno F, Lopez-Gonzalez JS, Galindo-Rodriguez G, Prado-Garcia H, Bajana S, Sanchez-Torres C: Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells. Cancer Immunol Immunother. 2006, 55: 598-611.PubMed
79.
Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J: Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood. 2007, 110: 4319-4330.PubMed
80.
Lawrence T, Natoli G: Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011, 11: 750-761.PubMed
81.
Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N: IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol. 2011, 12: 231-238.PubMed
82.
Martinez FO: Regulators of macrophage activation. Eur J Immunol. 2011, 41: 1531-1534.PubMed
83.
Murdoch C, Giannoudis A, Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood. 2004, 104: 2224-2234.PubMed
84.
Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ: CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem. 2009, 284: 34342-34354.PubMedCentralPubMed
85.
Zhang J, Patel L, Pienta KJ: CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010, 21: 41-48.PubMedCentralPubMed
86.
Choy E: Inhibiting interleukin-6 in rheumatoid arthritis. Curr Rheumatol Rep. 2008, 10: 413-417.PubMed
87.
Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA: Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer. Clin Cancer Res. 2011, 17: 6083-6096.PubMedCentralPubMed
88.
Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996, 2: 1096-1103.PubMed
89.
90.
Brown JR, Dubois RN: COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005, 23: 2840-2855.PubMed
91.
Herfs M, Herman L, Hubert P, Minner F, Arafa M, Roncarati P: High expression of PGE2 enzymatic pathways in cervical (pre)neoplastic lesions and functional consequences for antigen-presenting cells. Cancer Immunol Immunother. 2009, 58: 603-614.PubMed
92.
Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P: Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011, 118: 5498-5505.PubMedCentralPubMed
93.
Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S: Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005, 11: 7674-7682.PubMed
94.
Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 2007, 81: 15-27.PubMed
95.
Banerjee S, Lin CF, Skinner KA, Schiffhauer LM, Peacock J, Hicks DG: Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011, 71: 318-327.PubMed
96.
Stout RD, Suttles J: Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004, 76: 509-513.PubMedCentralPubMed
97.
Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N: Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol. 2005, 142: 481-489.PubMedCentralPubMed
98.
Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaya SN, Lotze MT: Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med. 2002, 195: 473-483.PubMedCentralPubMed
99.
Wirths S, Reichert J, Grunebach F, Brossart P: Activated CD8+ T lymphocytes induce differentiation of monocytes to dendritic cells and restore the stimulatory capacity of interleukin 10-treated antigen-presenting cells. Cancer Res. 2002, 62: 5065-5068.PubMed
100.
de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Lowik MJ, van der Hulst JM, Goedemans R: An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 2010, 70: 2707-2717.PubMed
101.
Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS: CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA. 2007, 104: 19446-19451.PubMedCentralPubMed
102.
DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N: CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell. 2009, 16: 91-102.PubMedCentralPubMed
103.
Corthay A, Skovseth DK, Lundin KU, Rosjo E, Omholt H, Hofgaard PO: Primary antitumor immune response mediated by CD4+ T cells. Immunity. 2005, 22: 371-383.PubMed
104.
Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L: Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology. 2010, 51: 154-164.PubMed
105.
DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF: Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discovery. 2011
106.
Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH: Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2010, 29: 1093-1102.PubMed
107.
Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S: Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. J Clin Oncol. 2008, 26: 848-855.PubMed
108.
Lonnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K: Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008, 8: 5-PubMedCentralPubMed
109.
Terlou A, van SM, Kleinjan A, Heijmans-Antonissen C, Santegoets LA, Beckmann I: Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int J Cancer. 2010, 127: 2831-2840.PubMed
110.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A: Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007, 13: 1050-1059.PubMed
111.
Kabelitz D: Expression and function of Toll-like receptors in T lymphocytes. Curr Opin Immunol. 2007, 19: 39-45.PubMed
112.
Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011, 331: 1612-1616.PubMedCentralPubMed
113.
van Kooten C, Banchereau J: CD40-CD40 ligand. J Leukoc Biol. 2000, 67: 2-17.PubMed
114.
Bos R, Sherman LA: CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010, 70: 8368-8377.PubMedCentralPubMed
115.
Nakanishi Y, Lu B, Gerard C, Iwasaki A: CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature. 2009, 462: 510-513.PubMedCentralPubMed
116.
Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008, 358: 2698-2703.PubMedCentralPubMed
117.
Verdegaal EM, Visser M, Ramwadhdoebe TH, van der Minne CE, van Steijn JA, Kapiteijn E: Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunol Immunother. 2011, 60: 953-963.PubMedCentralPubMed
118.
Melief CJ, van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer. 2008, 8: 351-360.PubMed
119.
Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F: Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA. 2010, 107: 11895-11899.PubMedCentralPubMed
Metadata
Title
Identification and manipulation of tumor associated macrophages in human cancers
Authors
Moniek Heusinkveld
Sjoerd H van der Burg
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-216

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Research

Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer

Research

Human saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages

Editorial

Combination therapy: the next opportunity and challenge of medicine

Research

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma

Research

Codon usage in vertebrates is associated with a low risk of acquiring nonsense mutations

Research

Liver mitochondrial dysfunction is reverted by insulin-like growth factor II (IGF-II) in aging rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits